Since pharmaceutical giant Eli Lilly(NYSE: LLY) reported earnings for the ... First, investors were not pleased with the ...
Zepbound and the diabetes treatment Mounjaro (which are the same underlying ... to meet the demand for Zepbound. In my view, Eli Lilly's relatively high payout ratio is no cause for concern. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback